<?xml version='1.0' encoding='utf-8'?>
<document id="26736983"><sentence text="A semi-mechanistic pharmacokinetic model of saquinavir combined with itraconazole in HIV-1-positive patients."><entity charOffset="44-54" id="DDI-PubMed.26736983.s1.e0" text="saquinavir" /><entity charOffset="69-81" id="DDI-PubMed.26736983.s1.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.26736983.s1.e0" e2="DDI-PubMed.26736983.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26736983.s1.e0" e2="DDI-PubMed.26736983.s1.e1" /></sentence><sentence text="The mechanism of drug-drug interaction between saquinavir, a protease inhibitor used effectively for HIV/AIDS treatment, and itraconazole, an azole antifungal agent, is hypothesized to involve competitive inhibition at CYP3A4 enzyme, an important drug metabolizing enzyme in humans"><entity charOffset="47-57" id="DDI-PubMed.26736983.s2.e0" text="saquinavir" /><entity charOffset="125-137" id="DDI-PubMed.26736983.s2.e1" text="itraconazole" /><entity charOffset="142-147" id="DDI-PubMed.26736983.s2.e2" text="azole" /><entity charOffset="132-136" id="DDI-PubMed.26736983.s2.e3" text="azole" /><pair ddi="false" e1="DDI-PubMed.26736983.s2.e0" e2="DDI-PubMed.26736983.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26736983.s2.e0" e2="DDI-PubMed.26736983.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26736983.s2.e0" e2="DDI-PubMed.26736983.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26736983.s2.e0" e2="DDI-PubMed.26736983.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26736983.s2.e1" e2="DDI-PubMed.26736983.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26736983.s2.e1" e2="DDI-PubMed.26736983.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26736983.s2.e1" e2="DDI-PubMed.26736983.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26736983.s2.e3" e2="DDI-PubMed.26736983.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26736983.s2.e3" e2="DDI-PubMed.26736983.s2.e2" /></sentence><sentence text=" The resulting interaction between these CYP3A4 substrates can be utilized clinically as a pharmacokinetic booster for prolonging saquinavir dosing regimen and/or decreasing saquinavir dose requirement in HIV/AIDS patients"><entity charOffset="130-140" id="DDI-PubMed.26736983.s3.e0" text="saquinavir" /><entity charOffset="174-184" id="DDI-PubMed.26736983.s3.e1" text="saquinavir" /><pair ddi="false" e1="DDI-PubMed.26736983.s3.e0" e2="DDI-PubMed.26736983.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26736983.s3.e0" e2="DDI-PubMed.26736983.s3.e1" /></sentence><sentence text=" To quantitatively describe this specific drug-drug interaction, based on the existing data, we aimed to develop a mathematical model incorporated with the competitive inhibition phenomena" /><sentence text=" PlotDigitizer was used to extract data from literature" /><sentence text=" Advance Continuous Simulating Language Extreme (ACSLX), a FORTRAN-based computer program, was employed as our developing tool" /><sentence text=" Our computer model simulations could successfully describe concentration-time course of saquinavir from selected pharmacokinetic studies in HIV-1-positive patients"><entity charOffset="89-99" id="DDI-PubMed.26736983.s7.e0" text="saquinavir" /></sentence><sentence text=" To extend the model's utility as an aid in saquinavir dosage regimens, the developed model may be applied to other HIV/AIDS patients in genuine clinical settings" /><sentence text=" " /></document>